<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84014">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957449</url>
  </required_header>
  <id_info>
    <org_study_id>13-103</org_study_id>
    <nct_id>NCT01957449</nct_id>
  </id_info>
  <brief_title>Propranolol in Severely Burned Children</brief_title>
  <official_title>Safety and Efficacy of Propranolol in Severely Burned Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of administration of propranolol for reducing heart
      rate and blood pressure in burn injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other purposes of this study are to study the effect on muscle function, the infectious
      process, sepsis, systemic inflammation and long-term scarring.  Quality of life will also be
      looked at over time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Resting heart rate multiplied by the systolic blood pressure measurement= rate pressure product</measure>
    <time_frame>Measured during acute hospital stay, an average of 4 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multiply the subjects resting heart rate and systolic blood pressure measurements and average every 24 hours while hospitalized (an average of 4 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>time of randomization up to one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of deaths will be compared between placebo group and propranolol treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol by mouth given daily throughout hospitalization for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth given daily throughout hospitalization for up to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol by mouth given daily throughout hospitalization for up to 12 months</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Metroprolol</other_name>
    <other_name>inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth given daily throughout hospitalization for up to 12 months.</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burns covering &gt;30% of the total body surface are

          -  Age of 0.5 to 18 years

          -  Patient arrival to the burn center within 96 hours (4 days) of burn injury

          -  Require &gt; 1 surgical procedure

        Exclusion Criteria:

          -  Pregnancy

          -  Known history of AIDS, ARC, or HIV

          -  History of cancer within 5 years

          -  Existence of pre-morbid conditions

          -  Asthma

          -  Congestive heart failure (measured ejection fraction &lt; 20%)

          -  Medical condition requiring glucocorticoid treatment

          -  Burn injury due to chemical burns

          -  Burn injury due to deep electrical injury (decision of hospital PI)

          -  Presence of anoxic brain injury that is not expected to result in complete
             recovery

          -  Decision not to treat due to burn injury severity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Reed, RN</last_name>
    <phone>409-770-6987</phone>
    <email>ca2reed@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Benjamin, RN</last_name>
    <phone>409-770-6731</phone>
    <email>dbenjami@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Greenhalgh, MD</last_name>
      <email>DGHalgh@shrinenet.org</email>
    </contact>
    <investigator>
      <last_name>David Greenhalgh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Sheridan, MD</last_name>
      <email>rsheridan@partners.org</email>
    </contact>
    <investigator>
      <last_name>Robert Sheridan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Kagan, MD</last_name>
      <email>rkagan@shrinenet.org</email>
    </contact>
    <investigator>
      <last_name>Richard Kagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Reed, BSN</last_name>
      <phone>409-770-6987</phone>
      <email>ca2reed@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deb Benjamin, MSN</last_name>
      <phone>409-770-6731</phone>
      <email>dbenjami@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David N Herndon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
